At a neighborhood convenience store in Brooklyn, a cashier rang up a tiny vial the shop was promoting as retatrutide, a next-generation weight-loss peptide that is still in clinical trials. The quick, low-key sale, quietly caught on camera, shows how fast demand for powerful new obesity treatments has jumped from doctors' offices to everyday retail counters. Public-health officials warn that products sold outside regulated medical channels can be mislabeled, contaminated or dangerously misdosed.
CBS News correspondent Adam Yamaguchi visited the store and recorded the sale, capturing the vial passed from behind the counter and the cashier ringing it up at the register, as reported by CBS News. The footage is part of a broader CBS investigation that found unapproved versions of retatrutide for sale online and in clinics nationwide. The on-the-ground example in Brooklyn highlights the gap between a headline-making trial drug and what is actually being offered in some neighborhoods.
Retatrutide is investigational and not approved for general use, and federal guidance says the compound cannot be legally used in compounding, according to the U.S. Food and Drug Administration. The agency has warned companies selling products labeled “for research use only” that their marketing and dosing instructions amount to distribution of unapproved drugs. That makes retail sales, even from a bodega counter, potentially subject to enforcement action.
Those enforcement concerns come as investigators say a wide gray market has already taken hold. A CBS News project identified more than 120 websites and over 50 U.S. clinics advertising or prescribing retatrutide outside clinical trials. In the same reporting, America's Poison Centers data showed human exposures to products labeled as retatrutide rose sharply in early 2026, a trend that coincided with rising reports of severe gastrointestinal and cardiovascular complaints, as detailed by CBS News. Public safety advocates say the data suggest many vials being sold online or in clinics may not be what they claim.
Consumer watchdogs say the market has outpaced federal action. A report from Public Citizen documents multiple hospitalizations tied to unapproved peptide products and notes that the FDA has issued warning letters while many sellers continue to advertise retatrutide, according to Public Citizen. The group argues that influencer promotion and lax enforcement have helped normalize unsafe access to injectable drugs.
Why Regulators Are Worried
Testing in independent labs has also turned up alarming inconsistencies. An investigative analysis in Australia found that one vial bought online and labeled retatrutide contained nearly double the concentration listed on the label, raising overdose concerns, as reported by ABC News. Experts say that incorrect concentration or contaminating fill materials can produce severe dehydration, electrolyte loss and other life-threatening reactions. Those risks are amplified when patients self-inject at home without clinical monitoring.
Legal and Public-Safety Implications
Federal law treats unapproved drugs and misbranded active pharmaceutical ingredients as illegal to distribute for human use, and the FDA has used warning letters to push back on suppliers and sellers, as in a recent letter to Darmerica that documents manufacturing and labeling violations. The agency's Darmerica letter lays out failures in current good manufacturing practice oversight and distribution that it says make APIs adulterated or misbranded, a legal framework regulators can use to pursue enforcement. Practitioners and clinics that dispense or administer unapproved peptides outside authorized trials may face civil liability or state pharmacy discipline.
Neighbors who see these products on store shelves are urged to treat them as potentially dangerous and avoid buying or injecting them. If someone has been exposed or is feeling unwell after a peptide injection, call Poison Help at 1-800-222-1222 or visit PoisonHelp.org for immediate guidance from medical toxicology specialists. Health officials advise discussing weight-loss drugs only with licensed clinicians and to enroll in clinical trials if interested in investigational therapies.
